Unassociated Document Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., chosen to lecture at the 2009 British Pharmaceutical Conference in Manchester, England

Chief Scientific Officer, Miriam Kidron, Ph.D., chosen to lecture at the 2009

British Pharmaceutical Conference in Manchester, England

Israel - August 18, 2009- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)

(http://www.oramed.com), a developer of alternative drug delivery systems,

announced today that Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D. was

chosen to present an overview of the clinical development of Oramed's Oral

Insulin capsule at science@BPC

of the 2009 British Pharmaceutical Conference ("BPC"), in Manchester,

England on September 9, 2009.

Science@BPC is an event that

is the result of the collaboration between two organizations, the Royal

Pharmaceutical Society of Great Britain and the Academy of Pharmaceutical

Sciences. The two organizations describe the event as "the UK's premier

medicines discovery and development event, showcasing excellence in the

pharmaceutical sciences." The focus of the BPS

this year is the innovative discovery, delivery, and diagnostic technologies

aimed at fighting cancer, infectious diseases and diabetes.

Kidron will present her lecture titled: "Oral Insulin: From Bench to Humans"

during the session titled: "Delivering Anti-diabetic Medicines." The

lecture will begin at 2:15 pm GMT (9:15 am EST, 6:15 am PST) on September 9,

2009. Dr. Kidron commented "Oramed is pleased to have been invited to the BPC to

share the clinical development of its Oral Insulin Capsule with the

pharmaceutical community."

Oramed Pharmaceuticals

Pharmaceuticals is a technology pioneer in the field of oral delivery solutions

for drugs and vaccines presently delivered via injection. Oramed is seeking

to revolutionize the treatment of diabetes through its patented flagship

product, an orally ingestible insulin capsule currently in phase 2 clinical

trials. Established in 2006, Oramed's technology is based on over 25 years of

research by top research scientists at Jerusalem's Hadassah Medical Center. The

Company's corporate and R&D headquarters are based in

information, please visit www.oramed.com.

Some of the statements contained in

this press release are forward-looking statements which involve known and

unknown risks, uncertainties and other factors which may cause the actual

results, performance or achievements of the company, or industry results, to be

materially different from any future results, performance or achievements

expressed or implied by such forward looking statements, including the risks and

uncertainties related to the progress, timing, cost, and results of clinical

trials and product development programs; difficulties or delays in obtaining

regulatory approval for our product candidates; competition from other

pharmaceutical or biotechnology companies; and the company's ability to obtain

additional funding required to conduct its research, development and

commercialization activities. Please refer to the company's filings with the

Securities and Exchange Commission for a comprehensive list of risk factors that

could cause actual results, performance or achievements of the company to differ

materially from those expressed or implied in such forward looking statements.

The company undertakes no obligation to update or revise any forward-looking

and Investor Relations Contacts:

Email: tara@oramed.com